Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method.

Salem ESB, Murakami K, Takahashi T, Bernhard E, Borra V, Bethi M, Nakamura T.

J Vis Exp. 2018 Oct 23;(140). doi: 10.3791/58323.

PMID:
30417869
2.

Hepatic Ago2-mediated RNA silencing controls energy metabolism linked to AMPK activation and obesity-associated pathophysiology.

Zhang C, Seo J, Murakami K, Salem ESB, Bernhard E, Borra VJ, Choi K, Yuan CL, Chan CC, Chen X, Huang T, Weirauch MT, Divanovic S, Qi NR, Thomas HE, Mercer CA, Siomi H, Nakamura T.

Nat Commun. 2018 Sep 10;9(1):3658. doi: 10.1038/s41467-018-05870-6.

3.

Circulating Tumor DNA Assays in Clinical Cancer Research.

Ossandon MR, Agrawal L, Bernhard EJ, Conley BA, Dey SM, Divi RL, Guan P, Lively TG, McKee TC, Sorg BS, Tricoli JV.

J Natl Cancer Inst. 2018 Sep 1;110(9):929-934. doi: 10.1093/jnci/djy105. Review.

4.

Accurate, Precision Radiation Medicine: A Meta-Strategy for Impacting Cancer Care, Global Health, and Nuclear Policy and Mitigating Radiation Injury From Necessary Medical Use, Space Exploration, and Potential Terrorism.

Coleman CN, Prasanna PGS, Bernhard EJ, Buchsbaum JC, Ahmed MM, Capala J, Obcemea C, Deye JA, Pistenmma DA, Vikram B, Bernier J, Dosanjh M.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):250-253. doi: 10.1016/j.ijrobp.2018.02.001. No abstract available.

PMID:
29726348
5.

Whole-Mount Adult Ear Skin Imaging Reveals Defective Neuro-Vascular Branching Morphogenesis in Obese and Type 2 Diabetic Mouse Models.

Yamazaki T, Li W, Yang L, Li P, Cao H, Motegi SI, Udey MC, Bernhard E, Nakamura T, Mukouyama YS.

Sci Rep. 2018 Jan 11;8(1):430. doi: 10.1038/s41598-017-18581-7.

6.

The Future of Radiobiology.

Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ.

J Natl Cancer Inst. 2018 Apr 1;110(4):329-340. doi: 10.1093/jnci/djx231.

7.

Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.

Takebe N, Ahmed MM, Vikram B, Bernhard EJ, Zwiebel J, Norman Coleman C, Kunos CA.

Semin Radiat Oncol. 2016 Oct;26(4):271-80. doi: 10.1016/j.semradonc.2016.06.005. Epub 2016 Jun 15. Review.

PMID:
27619249
8.

Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.

Coleman CN, Higgins GS, Brown JM, Baumann M, Kirsch DG, Willers H, Prasanna PG, Dewhirst MW, Bernhard EJ, Ahmed MM.

Clin Cancer Res. 2016 Jul 1;22(13):3138-47. doi: 10.1158/1078-0432.CCR-16-0069. Epub 2016 May 6. Review.

9.

Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations.

Stone HB, Bernhard EJ, Coleman CN, Deye J, Capala J, Mitchell JB, Brown JM.

Transl Oncol. 2016 Feb;9(1):46-56. doi: 10.1016/j.tranon.2016.01.002. Review.

10.

Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: In Regard to Brachman et al.

Brown M, Bernhard E, Mitchel J, Stone H.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):210-211. doi: 10.1016/j.ijrobp.2015.08.047. No abstract available.

PMID:
26700716
11.

Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation.

Prasanna PG, Narayanan D, Hallett K, Bernhard EJ, Ahmed MM, Evans G, Vikram B, Weingarten M, Coleman CN.

Radiat Res. 2015 Sep;184(3):235-48. doi: 10.1667/RR14186.1. Epub 2015 Aug 18.

12.

A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice.

Pai CC, Deegan RS, Subramanian L, Gal C, Sarkar S, Blaikley EJ, Walker C, Hulme L, Bernhard E, Codlin S, Bähler J, Allshire R, Whitehall S, Humphrey TC.

Nat Commun. 2014 Jun 9;5:4091. doi: 10.1038/ncomms5091.

13.

Harnessing the potential of radiation-induced immune modulation for cancer therapy.

Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN.

Cancer Immunol Res. 2013 Nov;1(5):280-4. doi: 10.1158/2326-6066.CIR-13-0141. Review.

14.

Lessons learned from radiation oncology clinical trials.

Liu FF; workshop participants, Okunieff P, Bernhard EJ, Stone HB, Yoo S, Coleman CN, Vikram B, Brown M, Buatti J, Guha C.

Clin Cancer Res. 2013 Nov 15;19(22):6089-100. doi: 10.1158/1078-0432.CCR-13-1116. Epub 2013 Sep 16. Review.

15.

Normal tissue protection for improving radiotherapy: Where are the Gaps?

Prasanna PG, Stone HB, Wong RS, Capala J, Bernhard EJ, Vikram B, Coleman CN.

Transl Cancer Res. 2012 Jun;1(1):35-48.

16.

G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency.

Im JH, Tapmeier T, Balathasan L, Gal A, Yameen S, Hill S, Smart S, Noterdaeme O, Kelly M, Brady M, Fu W, Kruse K, Bernhard EJ, Augustin HG, Muschel RJ.

Int J Cancer. 2013 Jan 15;132(2):315-26. doi: 10.1002/ijc.27677. Epub 2012 Jul 3.

17.

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.

Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Radiat Oncol. 2012 Mar 27;7:48. doi: 10.1186/1748-717X-7-48.

18.

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.

Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Cancer Res. 2012 Jan 1;72(1):239-48. doi: 10.1158/0008-5472.CAN-11-2263. Epub 2011 Nov 22.

19.

Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo.

Qayum N, Im J, Stratford MR, Bernhard EJ, McKenna WG, Muschel RJ.

Clin Cancer Res. 2012 Jan 1;18(1):161-9. doi: 10.1158/1078-0432.CCR-11-1413. Epub 2011 Nov 7.

20.

New translational possibilities for microenvironmental modulation of radiosensitivity.

Glazer PM, Le QT, Bristow R, Helleday T, Pelroy R, Bernhard EJ.

Radiat Res. 2011 Sep;176(3):412-4. Epub 2011 Jul 8. Review. No abstract available.

PMID:
21867431
21.

Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010.

Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ; NCI Workshop Participants.

Radiat Res. 2011 Sep;176(3):e0016-21. Epub 2011 Jul 8. No abstract available.

PMID:
21867428
22.

Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities: Report of an NCI Workshop held September 1-3, 2010.

Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ.

Radiat Res. 2011 Jul 8. [Epub ahead of print] No abstract available.

PMID:
21740251
23.

Interventions that induce modifications in the tumor microenvironment.

Bernhard EJ.

Cancer Radiother. 2011 Aug;15(5):376-82. doi: 10.1016/j.canrad.2011.01.007. Epub 2011 May 14. Review.

PMID:
21571567
24.

A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.

Higgins GS, Prevo R, Lee YF, Helleday T, Muschel RJ, Taylor S, Yoshimura M, Hickson ID, Bernhard EJ, McKenna WG.

Cancer Res. 2010 Apr 1;70(7):2984-93. doi: 10.1158/0008-5472.CAN-09-4040. Epub 2010 Mar 16. Erratum in: Cancer Res. 2010 May 1;70(9):3853.

25.

Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.

Maity A, Bernhard EJ.

Cancer Res. 2010 Mar 15;70(6):2141-5. doi: 10.1158/0008-5472.CAN-09-3615. Epub 2010 Feb 23. Review.

26.

Cell signalling and radiation survival: the impact of protein phosphatases.

Hamilton J, Bernhard EJ.

Int J Radiat Biol. 2009 Nov;85(11):937-42. doi: 10.3109/09553000903232827. Review.

PMID:
19895270
27.

Tumor vascular changes mediated by inhibition of oncogenic signaling.

Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG, Bernhard EJ.

Cancer Res. 2009 Aug 1;69(15):6347-54. doi: 10.1158/0008-5472.CAN-09-0657. Epub 2009 Jul 21.

28.

Phosphatase inhibition and cell survival after DNA damage induced by radiation.

Hamilton J, Grawenda AM, Bernhard EJ.

Cancer Biol Ther. 2009 Aug;8(16):1577-86. Epub 2009 Aug 8. Erratum in: Cancer Biol Ther. 2010 Apr 15;9(8):652-4.

PMID:
19571665
29.

Conventional radiotherapy or hypofractionation? A study of molecular changes resulting from different radiation fractionation schemes.

Hamilton J, Higgins G, Bernhard EJ.

Cancer Biol Ther. 2009 May;8(9):774-6. Epub 2009 May 4. No abstract available.

PMID:
19395860
30.

Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.

Kim IA, No M, Lee JM, Shin JH, Oh JS, Choi EJ, Kim IH, Atadja P, Bernhard EJ.

Radiother Oncol. 2009 Jul;92(1):125-32. doi: 10.1016/j.radonc.2009.03.008. Epub 2009 Mar 28.

PMID:
19329208
31.

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.

Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S, Bernhard EJ.

Cancer Res. 2008 Jul 15;68(14):5915-23. doi: 10.1158/0008-5472.CAN-08-0757.

32.

Progress towards the use of HIV protease inhibitors in cancer therapy.

Bernhard EJ, Brunner TB.

Cancer Biol Ther. 2008 May;7(5):636-7. Epub 2008 May 10.

PMID:
18421253
33.

Tumor growth signaling inhibition: targeting multiple pathways.

Sampson O, Bernhard E.

Cancer Biol Ther. 2008 Feb;7(2):319-21. Epub 2008 Feb 18. No abstract available.

PMID:
18347431
34.

Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.

Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, Hahn SM, Gupta AK, Maity A.

Cancer Res. 2007 May 1;67(9):4467-73.

35.

Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1.

Cordes N, Frick S, Brunner TB, Pilarsky C, Grützmann R, Sipos B, Klöppel G, McKenna WG, Bernhard EJ.

Oncogene. 2007 Oct 18;26(48):6851-62. Epub 2007 Apr 30.

PMID:
17471232
36.

Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna WG, Bernhard EJ.

Neoplasia. 2007 Apr;9(4):341-8.

37.

Pancreatic cancer inhibition by specific knockdown of K-ras mutant allele expression.

Bernhard EJ.

Cancer Biol Ther. 2007 Feb;6(2):293-4. Epub 2007 Feb 12. No abstract available.

PMID:
17387263
38.

Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.

Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, Koch CJ, Hahn SM, Maity A.

Cancer Res. 2006 Sep 15;66(18):9252-9.

39.

Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines.

Cengel KA, Deutsch E, Stephens TC, Voong KR, Kao GD, Bernhard EJ.

Cancer Biol Ther. 2006 Sep;5(9):1206-10. Epub 2006 Sep 11.

PMID:
16969121
41.

Cardiac output measurement by pulse dye densitometry in cardiac surgery.

Baulig W, Bernhard EO, Bettex D, Schmidlin D, Schmid ER.

Anaesthesia. 2005 Oct;60(10):968-73.

42.

Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.

Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, Bernhard EJ.

Cancer Res. 2005 Sep 15;65(18):8433-41.

43.

Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.

Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, Birnbaum MJ, Bernhard EJ.

Cancer Res. 2005 Sep 1;65(17):7902-10.

44.

Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature.

Shi Y, Lee CS, Wu J, Koch CJ, Thom SR, Maity A, Bernhard EJ.

Head Neck. 2005 May;27(5):362-9.

PMID:
15818558
45.

DR5 knockout mice are compromised in radiation-induced apoptosis.

Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T, El-Deiry WS.

Mol Cell Biol. 2005 Mar;25(5):2000-13.

46.

p53-dependent induction of serine proteases in irradiated mouse colon.

Lin SW, Cook M, Finnberg N, Bernhard E, Baldwin D, El-Deiry WS.

Cancer Biol Ther. 2004 Dec;3(12):1290-7. Epub 2004 Dec 9.

PMID:
15684611
47.

Farnesyltransferase inhibition: who are the Aktors?

Bernhard EJ.

Cancer Biol Ther. 2004 Nov;3(11):1099-101. Epub 2004 Nov 16. No abstract available.

PMID:
15640614
48.

Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.

Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS.

Cancer Cell. 2004 Dec;6(6):597-609.

49.

Radiation sensitization by inhibition of activated Ras.

Brunner TB, Hahn SM, McKenna WG, Bernhard EJ.

Strahlenther Onkol. 2004 Nov;180(11):731-40. Review.

PMID:
15549191
50.

Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.

Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ.

Prostate. 2005 Jan 1;62(1):69-82.

PMID:
15389805

Supplemental Content

Loading ...
Support Center